<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05094193</url>
  </required_header>
  <id_info>
    <org_study_id>HTHEC-2021-29</org_study_id>
    <nct_id>NCT05094193</nct_id>
  </id_info>
  <brief_title>Trocar-site Infiltration Versus TAP-block</brief_title>
  <official_title>Trocar-site Infiltration With Ropivacaine Versus Tranversus Abdominis Plane Block Following Laparoscopic Cholecystectomy: a Double-blinded, Randomized-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tunis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tunis University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For symptomatic gall bladder disorders (cholelithiasis and cholecystitis), laparoscopic&#xD;
      cholecystectomy (LC) has been considered as the gold standard treatment. However, these&#xD;
      minimally invasive technique is associated with acute moderate pain during the 24 hours&#xD;
      postoperative, which is routinely managed using opioids. The transversus abdominis plane&#xD;
      (TAP) block has been used as part of a multimodal analgesia strategy. Besides, Wang et al&#xD;
      found that TAP block is more effective than a conventional pain control, but not&#xD;
      significatively different from another local incisional pain control that is port site&#xD;
      infiltration.So, the aim of this study, is to compare the analgesic efficacy and safety of&#xD;
      trocar-site infiltration with ropivacaine with ultrasound-guided TAP block following&#xD;
      laparoscopic cholecystectomy when used as part of multimodal analgesia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute postoperative pain</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Visual analog scale (VAS) 0: &quot;no pain&quot; to 10: &quot;severe pain&quot; at rest and cough</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total opioid consumption</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>up to 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative nausea and vomiting</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction and quality of recovery</measure>
    <time_frame>Day 1</time_frame>
    <description>QoR-40 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of shoulder pain</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complication</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Ileus, wound infection, wound abscess</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Laparoscopic Cholecystectomy</condition>
  <arm_group>
    <arm_group_label>Trocar-site infiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trocar-site infiltration with 20 mL of ropivacaine 0.375% (6 mL in 10 mm trocar site and 4 mL in 5 mm trocar site) associated with bilateral TAP block with 20 mL of normal saline in each side</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAP block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trocar-site infiltration with 20 mL of normal saline associated with bilateral TAP block with 20 mL of ropivacaine 0.375% in each side</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trocar-site infiltration</intervention_name>
    <description>20 mL of ropivacaine 0.375% (6 mL in 10 mm trocar site and 4 mL in 6 mm trocar site)</description>
    <arm_group_label>Trocar-site infiltration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAP block</intervention_name>
    <description>bilateral ultrasound-guided TAP block with 20 mL of ropivacaine 0.375% in each side</description>
    <arm_group_label>TAP block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trocar site infiltration placebo</intervention_name>
    <description>20 mL of normal saline</description>
    <arm_group_label>TAP block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAP block placebo</intervention_name>
    <description>bilateral ultrasound-guided TAP block with 20 mL of normal saline in each side</description>
    <arm_group_label>Trocar-site infiltration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI &lt; 30 kg/m2&#xD;
&#xD;
          -  Scheduled for laparoscopic cholecystectomy&#xD;
&#xD;
          -  ASA grade I, II and III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bile duct exploration, insertion of a T-drain or patients with acute cholecystitis&#xD;
&#xD;
          -  Conversion to open cholecystectomy or if the surgery exceeded 200 minutes&#xD;
&#xD;
          -  Severe systemic disease&#xD;
&#xD;
          -  Patients on analgesics for any reason&#xD;
&#xD;
          -  History of allergy to local anesthetics&#xD;
&#xD;
          -  An ongoing pregnancy&#xD;
&#xD;
          -  Patient refusal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BEN FADHEL Kamel, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Habib Thameur Hospital of Tunis, Department of Anesthesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DAGHMOURI Mohamed Aziz, M.D</last_name>
    <phone>0029442474</phone>
    <email>aziz.daghmouri@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Habib Thameur Hospital</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Aziz Daghmouri</last_name>
      <email>aziz.daghmouri@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 3, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tunis University</investigator_affiliation>
    <investigator_full_name>Daghmouri Mohamed Aziz</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Acute pain management</keyword>
  <keyword>Ropivacaine</keyword>
  <keyword>Trocar-site infiltration</keyword>
  <keyword>TAP-block</keyword>
  <keyword>Laparoscopic cholecystectomy</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

